Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Elevation of the leukocyte enzyme myeloperoxidase (MPO) in stable coronary artery disease (CAD) patients in contrast to unstable CAD patients is controversial and its relationship with some inflammatory and noninflammatory markers such as oxidized LDL (ox-LDL) and nitric oxide (NO) in the CAD patients has not been evaluated yet. Evaluation of these relationships is the aim of the study.Also the relationships between MPO and some other inflammatory biomarker such as leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine are examined. This study includes 50 stable CAD, 50 unstable CAD patients and 50 controls. Plasma MPO, ox-LDL, leptin, adiponectin, sPLA2 levels are determined using enzyme immunoassay.Homocysteine and 3-nitrotyrosine are measured using HPLC-fluorescence method. Plasma total NO and other risk factors such as lipid profile, hypertension, smoking, diabetes mellitus and familial history of CAD are also determined in the patients. Results are statistically analysed and the association between all markers are assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

coronary artery disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stable, Unstable , control

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stable and unstable patients with angiographically documented coronary artery disease.
* Control subjects without angiographically documented coronary artery disease.

Exclusion Criteria

* Patients with recent (with in 6 month) myocardial infarction or cardiovascular events,
* surgery (with in 3 month),
* cancer and
* infective or inflammatory diseases were not included in the study.

Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

School of pharmacy and pharmaceutical sciences

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Saedzaaldin Samsamshariat, PhD

Role: STUDY_DIRECTOR

- Clinical Biochemistry Department, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Isfahan Cardiovascular Research Center

Isfahan, Isfahan, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

388417

Identifier Type: -

Identifier Source: org_study_id